-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $47

Benzinga·03/03/2026 16:45:33
Listen to the news
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $50 to $47.